Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05259839 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 283
- Enrollment target
- 20
- Study locations
NCT05259839 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 283 participants, above the 149-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05259839, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 283 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of etentamig, followed by a dose expansion phase to confirm the dose. Approximately 320 adult participants with R/R MM will be enrolled in the study in approximately 48 sites worldwide. Participants will receive intravenous (IV) etentamig co-administered with oral/IV Pd, oral/IV Rd, or oral/IV/subcutaneous (SC) Dd in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Etentamig
Study Locations (20)
Victoria
- Monash Health - Monash Medical Centre /ID# 244403 - Clayton
- St Vincent's Hospital Melbourne /ID# 256879 - Fitzroy Melbourne
- Peter MacCallum Cancer Ctr /ID# 256880 - Melbourne
Florida
- Sylvester Comprehensive Cancer Center /ID# 243673 - Miami
- Moffitt Cancer Center /ID# 243437 - Tampa
Massachusetts
- Dana-Farber Cancer Institute /ID# 249529 - Boston
- University of Massachusetts - Worcester /ID# 243977 - Worcester
New York
- Rutenberg Cancer Center /ID# 244647 - New York
- Memorial Sloan Kettering Cancer Center /ID# 244656 - New York
New South Wales
- St George Hospital /ID# 243740 - Kogarah
- Calvary Mater Newcastle /ID# 243730 - Waratah
Arkansas
- University of Arkansas for Medical Sciences /ID# 243096 - Little Rock
Maryland
- University of Maryland, Baltimore /ID# 243679 - Baltimore
Michigan
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 243438 - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2033-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05259839
The ClinicalTrials.gov registry entry for NCT05259839 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 149-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (90% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT05259839 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Victoria, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05259839 about?
NCT05259839 is a clinical study titled "A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma". Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or ...
What is the current status of trial NCT05259839?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 283 participants. The study started on 2022-10-20. Estimated completion is 2033-09.
What conditions does trial NCT05259839 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05259839?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Etentamig (DRUG).
Who is sponsoring clinical trial NCT05259839?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05259839 being conducted?
This trial has 20 study locations across Arkansas, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.